David Schull

President of Russo Partners, a communications firm that works with innovators in healthcare and technology — and the home of the Sports-Health Alliance

[David Schull @davidschull]

Free event to celebrate students, raise asthma awareness in Las Vegas https://t.co/d7Y9uqDLvL

[David Schull @davidschull]

Cocrystal Pharma Appoints James Sapirstein, Biopharma https://t.co/uXssi3oqgD

[David Schull @davidschull]

FibroBiologics Announces First Patients Dosed in Phase 1/2 https://t.co/fsx7cW6Ooy

[David Schull @davidschull]

NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - https://t.co/hnJKUPzZc6 https://t.co/3eiiX4KC3F

[David Schull @davidschull]

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - FibroBiologics (N - Benzinga https://t.co/ouVJ9Hl4bJ

[David Schull @davidschull]

NTRA & Diakonos partner to use Signatera in refractory melanoma trial https://t.co/FWQ3pM7H2Z

[David Schull @davidschull]

NeuroOne Reports 72 Percent Product Revenue Growth For OneRF System https://t.co/uZwyP8BnwX

[David Schull @davidschull]

The CFO helping to bring his biotech “to the finish line” https://t.co/Hk6hnFoNPb

[David Schull @davidschull]

@BioWorld @ApreaTX Great article and segment @russopartners

[FibroBiologics @FibroBiologics]

Stem cells dominate regenerative medicine.
But fibroblasts outnumber them 5,000 to 1.

$FBLG #Fibroblasts #Biotech #RegenerativeMedicine

[FibroBiologics @FibroBiologics]

.@FibroBiologics announced the first patients have been enrolled and dosed in the Phase 1/2 trial evaluating CYWC628 for diabetic foot ulcers. The prospective, multicenter, randomized study is being conducted across multiple sites in Australia and is designed to enroll up to 120 patients. The trial will evaluate the safety, tolerability, and efficacy of CYWC628, FibroBiologics’ investigational topically administered allogeneic fibroblast-spheroid cell-based therapy.

For more info, visit here: https://t.co/bfNoBzGziS

[David Schull @davidschull]

@CoyaTx @CDickerson_PFTP @alsnewstoday

[Coya Therapeutics @CoyaTx]

We’re honored to partner with former Yankees outfielder @CDickerson_PFTP to help raise awareness for people living with #ALS.

As a member of the baseball community, Chris understands the lasting impact of Lou Gehrig’s legacy and the importance of continuing the fight against this devastating disease. That’s why, on Lou Gehrig Day, we’re shining a spotlight on the urgent need for innovation and research we advance COYA 302 in our ongoing ALSTARS clinical trial.

To learn more about our trial: https://t.co/N9lrvI4B7d

#ClinicalTrials #NeurodegenerativeDisease #EndALS

[ALS TDI @ALSTDI]

Today, we honor Lou Gehrig, whose legacy continues to inspire the fight against ALS.

As we remember Lou, we also recognize the progress made possible by researchers, participants, advocates, and supporters working toward a future without ALS.

[David Schull @davidschull]

Aprea unveils APR-1051 Phase 1 data with partial responses | APRE Stock News https://t.co/cDHfN9MRuN

[David Schull @davidschull]

Former @Yankees outfielder Chris Dickerson is teaming with @CoyaTx to step up to the plate for people living with #ALS #LouGehrigDay

[David Schull @davidschull]

ProKidney Appoints Kenneth Locke as Chief Technical https://t.co/t6jP0szMWM

[David Schull @davidschull]

Bay Area Lyme Ventures Invests in Galaxy Diagnostics to https://t.co/pW5JW3dr9d

[David Schull @davidschull]

Cardiff Oncology Announces Presentation of Positive Results https://t.co/bhPMfHx2Jj

[David Schull @davidschull]

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash | The Healthcare Technology Report. https://t.co/OimnJ51PVm